NEW YORK, January 1, 2026, 16:58 ET — Market closed
Axsome Therapeutics shares jumped about 23% in the most recent session on Wednesday after the company said the U.S. Food and Drug Administration accepted its supplemental application for AXS-05 to treat agitation in Alzheimer’s disease and granted the filing priority review. The stock last traded at $182.64, after swinging between $148.79 and $184.40 on volume of about 3.1 million shares.
Why it matters now: priority review shortens the FDA’s review target to six months, versus 10 months under the standard process, pulling a key binary catalyst into the first half of 2026. Investors often reprice drug developers quickly when regulators put a hard decision date on a major program.
The filing also lands in a narrow competitive lane. Otsuka Pharmaceutical and Lundbeck’s Rexulti is the first FDA-approved treatment for agitation associated with dementia due to Alzheimer’s disease, leaving limited on-label competition if Axsome clears the agency.
“We are very pleased the FDA has accepted and granted priority review to our supplemental NDA,” Chief Executive Herriot Tabuteau said. The company said AXS-05 combines dextromethorphan and bupropion and is already sold in the U.S. as Auvelity for major depressive disorder; the Alzheimer’s agitation use would be a label expansion via a supplemental New Drug Application, or sNDA. BioSpace
Axsome also disclosed separate regulatory progress on AXS-12, saying FDA pre-NDA meeting minutes support an NDA filing for cataplexy in narcolepsy and that submission is on track for January 2026. Cataplexy is a sudden loss of muscle tone, often triggered by strong emotions, and the company said AXS-12 has FDA orphan-drug designation, which can confer benefits such as potential market exclusivity if approved.
On the Street, Mizuho analyst Graig Suvannavejh raised Axsome’s price target to $217 from $202 and kept an Outperform rating, citing the two “positive regulatory” updates and higher probability-of-success assumptions for both assets, according to a note carried by The Fly. TipRanks
The sharp move underscores how quickly sentiment can shift in single-product biotech when a regulatory timeline tightens. For Axsome, investors are now weighing the odds of an expansion for its flagship dextromethorphan-bupropion franchise against the execution risks that come with late-stage CNS drug reviews.
U.S. stock markets are closed Thursday for the New Year’s Day holiday and are set to reopen Friday.
Before the next session, traders will watch for any added detail around the timing and contents of the AXS-12 filing and whether the FDA signals any additional data needs once the package is submitted, given the company’s own caution that acceptance depends on the final filing review.
A larger marker sits further out: the FDA’s April 30 target action date for AXS-05, which puts label language and safety discussions in focus as the review advances. The company’s next quarterly update is also a near-term swing factor for positioning, though Axsome has not announced a date; MarketBeat lists an estimated report date of Feb. 17.
Technically, investors will be watching whether AXSM holds above the $150 area that roughly matched Wednesday’s session low and the prior close, after the stock’s jump pushed it into the low-$180s.
